Trial · NCT01932112
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
NCT01932112, Phase 3, Completed, Yong Seog Oh; results first posted 2016-04-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial). Trials, record NCT01932112. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01932112
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
- NCT number
- NCT01932112
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 378 participants, actual
- Lead sponsor
- Yong Seog Oh
- Conditions
- Atrial Fibrillation, Persistent Common Pulmonary Vein
- Interventions
- Adenosine arm
- First posted
- 2013-08-30
- Last updated
- 2017-04-26
- Results first posted
- 2016-04-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion | 5 minutes after IV adenosine | After pulmonary vein isolation, 20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection. |
| Secondary | Atrial Fibrillation Recurrence | between 0 and 12 months | At 1 month, 3 month, 6 month and 12 months post ablation routine clinic visits, will perform electrocardiographically documented by electrogram (At 1,3,6,12 months post ablation) and Holter monitoring (At 12 months post ablation) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion | 5 minutes after IV adenosine | participants | NUMBER | |
| SECONDARY | Atrial Fibrillation Recurrence | between 0 and 12 months |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion | Adenosine Arm | 92 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Adenosine Arm | 378 | |
| Overall Study | COMPLETED | Adenosine Arm | 378 | |
| Overall Study | NOT COMPLETED | Adenosine Arm | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | cough | Respiratory, thoracic and mediastinal disorders | Adenosine Arm | 2 | 378 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adenosine Arm | ||
| Total, other adverse events | Adenosine Arm | 0 | 378 |
| Total, serious adverse events | Adenosine Arm | 2 | 378 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26960977 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01932112
GET https://conductscience.org/api/trials/v1/NCT01932112/registered